Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study

Why did Trump suggest 80% China tariffs? How will US-UK trade deal impact consumers? Why was Newark airport's radar down again? What caused Panasonic's major job cuts? How did Google settle $1.4B Texas data claims? Why is Tesla cutting production this week? What risks do tariffs pose to US small businesses? How did Trump's tariffs affect Canada’s labor market? What’s behind Coinbase’s new 24/7 futures trading?

Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study

benzinga.com/general/biotech/25/05/45323158/protagonist-johnson-johnson-partnered-drug-shows-significant-skin-clearance-in-pivotal-psoriasis-

Protagonist Therapeutics Inc. (NASDAQ:PTGX), in collaboration with Johnson & Johnson (NYSE:JNJ), released new clinical data from the Phase 3 ICONIC-TOTAL study investigating icotrokinra for scalp and genital psoriasis.
Key findings from the high-impact skin sites cohort:
At week 16, 57%…

This story appeared on benzinga.com, 2025-05-09 15:59:32.